NRIX Q4 2025 Earnings
Reported Jan 28, 2026 at 4:03 PM ET · SEC Source
Q4 25 EPS
$-0.82
BEAT +10.85%
Est. $-0.92
Q4 25 Revenue
$13.6M
BEAT +1.22%
Est. $13.4M
vs S&P Since Q4 25
+0.7%
BEATING MARKET
NRIX +6.3% vs S&P +5.6%
Full Year 2025 Results
FY 25 EPS
$-3.05
FY 25 Revenue
$84.0M
Market Reaction
Did NRIX Beat Earnings? Q4 2025 Results
Nurix Therapeutics delivered a cleaner-than-expected Q4 fiscal 2025, posting a loss of $0.82 per share against a consensus estimate of $0.92, a beat of 10.85%, while revenue of $13.58 million edged ahead of the $13.41 million forecast by 1.22% and gr… Read more Nurix Therapeutics delivered a cleaner-than-expected Q4 fiscal 2025, posting a loss of $0.82 per share against a consensus estimate of $0.92, a beat of 10.85%, while revenue of $13.58 million edged ahead of the $13.41 million forecast by 1.22% and grew 2.2% year-over-year. The primary story behind the numbers, however, was the widening net loss to $78.22 million from $58.55 million a year ago, as R&D spending climbed to $83.02 million from $67.22 million to fund accelerating enrollment in the DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL. Data presented at ASH 2025 showed an 83% objective response rate in Phase 1a, lending clinical weight to that spending. The company ended the period with $592.90 million in cash after a $250.00 million equity offering, though investors have taken note of widening annual losses of $264.46 million and dilution concerns. Looking ahead, Nurix plans to initiate a global Phase 3 confirmatory trial comparing bexobrutideg to pirtobrutinib in the first half of 2026, with an autoimmune IND also targeted for the year.
Key Takeaways
- • Revenue increase for full year driven by $30 million in Sanofi license extension revenue
- • Research milestones of $7 million from Sanofi and $5 million from Pfizer during fiscal year 2025
- • $5 million clinical milestone from Gilead collaboration
- • Revenue partially offset by decrease as initial research terms for certain drug targets ended under Sanofi and Gilead collaborations
NRIX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
NRIX Revenue by Segment
With YoY comparisons, source: SEC Filings
“The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak™ registrational program for bexobrutideg and strengthened our balance sheet to support execution across our pipeline. With regulatory alignment on Phase 2 dose, compelling Phase 1 clinical data in CLL, and the continued advancement of our autoimmune and immuno-oncology programs, we believe we are well positioned to deliver the benefits of degrader-based medicines to significant populations of patients in need of new therapies.”
— Arthur T. Sands, Q4 2025 Earnings Press Release
NRIX Earnings Trends
NRIX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NRIX EPS Trend
Earnings per share: estimate vs actual
NRIX Revenue Trend
Quarterly revenue: estimate vs actual
NRIX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.76 | $-0.79 | -3.32% | $6.3M | -56.09% |
| Q4 25 BEAT FY | $-0.92 | $-0.82 | +10.85% | $13.6M | +1.22% |
| FY Full Year | — | $-3.05 | — | $84.0M | — |
| Q3 25 MISS | $-0.85 | $-1.03 | -21.08% | $7.9M | -50.85% |
| Q2 25 BEAT | $-0.74 | $-0.52 | +30.15% | $44.1M | +151.56% |